Imatinib is a small-molecule TKI targeting BCR-ABL fusion protein, KIT and PDGFR that was first developed for the treatment of chronic myeloid leukemia (CML), but currently is also used in the treatment of GISTs. This evidence concerns the gene PDGFRB and chronic myelogenous leukemia, BCR-ABL1 positive.